A Study of LY900020 in Healthy Chinese Participants
Status:
Completed
Trial end date:
2020-02-18
Target enrollment:
Participant gender:
Summary
This study will evaluate three new formulations of LY900020; a fixed dose, combination drug
developed for people with type 2 diabetes mellitus. The study will be conducted in healthy
participants to investigate the effect of different tablet formulations on the amount of
LY900020 in the bloodstream. Side effects and tolerability will be documented. The study will
last about 10 weeks for each participant, including screening and follow up. Screening is
required within 28 days prior to entering the study.